Real-world assessment of caregiver preference and compliance to treatment with twice-weekly versus daily rivastigmine patches in Alzheimer’s disease.
2024
García-Alberca JM, De la Guía P, Gris E et al.
Journal of Alzheimer´s Disease 2024, 102 (3) in press.
Connecting genomic and proteomic signatures of amyloid burden in the brain.
2024
Puerta R, de Rojas I, García-González P et al.
medRxiv 2024 Sep6:2024.09.06.24313124. doi:10.1101/2024.09.06.24313124.
Effectiveness of Vortioxetine Treatment on Depression and Cognitive Functions in Patients with Alzheimer’s Disease: A 12-Month, Retrospective, Observational Study.
2024
García-Alberca JM , De La Guia P, Gris E et al.
Journal of Personalized Medicine 2024, 14, 918.
A genome-wide associationmeta-analysis of all-cause and vascular dementia.
2024
Fongang B et al.
Alzheimer´s & Dementia 2024; doi: 10.1002/alz.14115. Online ahead of print.
An insertion within the SIRPβ1 gen shows a dual effect over Alzheimer’s disease cognitive decline altering the microglial response.
2024
García-Alberca JM, de Rojas I, Sánchez-Mejías E et al.
Journal of Alzheimer´s Disease 2023; 98: 601-618
Effect of Nordic Sensi® Chair on Behavioral and Psychological Symptoms of Dementia in Nursing Homes Residents: A Randomized Controlled Trial.
2023
García-Alberca JM, De la Rosa MD, Solo de Zaldívar P et al.
Journal of Alzheimer´s Disease 96 2023 1609–1622
Antidepressants in patients with neurological disorders.
2023
García-Alberca JM.
Kranion. 2023; 18:108-15
Genetic Associations Between Modifiable Risk Factors and Alzheimer Disease.
2023
Luo J, Thomassen JQ, Bellenguez C et al.
JAMA Netw Open. 2023 May 1;6(5):e2313734
Multi-ancestry HLA analysis in Alzheimer’s and Parkinson’s diseases uncovers a shared adaptive immune response mediated by HLA-DRB1*04.
2023
GMignot et al. 120(36):e2302720120
The Proceedings of the National Academy of Sciences (PNAS)
Effects of antidepressant treatment on cognition in patients with Alzheimer’s disease.
2023
Garcia-Alberca JM,.
Kranion 2023; 18:27-33
An intragenic duplication within SIRPβ1 shows a dual effect over Alzheimer’s disease cognitive decline altering the microglial response.
2022
Garcia-Alberca JM, de Rojas I, Sanchez-Mejias E et al.
medRxiv 2022, https://doi.org/10.1101/2022.11.19.22282342
Rare missense variant (R251G) on APOE counterbalances the Alzheimer’s disease risk associated with APOE‐ε4.
2022
Guen YL, Belloy ME, Grenier‐Boley B et al.
Alzheimer’s & Dementia 18, e060114 2022
Identification of a sex-specific genetic signature in dementia with Lewy bodies: a meta-analysis of genome-wide association studies.
2022
Gibbons E, Rongve A, de Rojas I et al.
MedRxiv 2022
Combined treatment with Ginkgo biloba extract EGb 761 plus acetylcholinesterase inhibitors improved cognitive function and neuropsychiatric symptoms in patients with mild cognitive impairment.
2022
García-Alberca JM, Gris E, Mendoza S.
Alzheimers Dement (N Y) 2022; Aug 2;8(1):e12338.
Effects of tianeptine treatment on depression and cognitive function in patients with Alzheimer’s disease: a 12-month retrospective observational study.
2022
García-Alberca JM, Gris E, De la Guía P, Silvia Mendoza S.
Journal of Alzheimer´s Disease 2022; 88: 707–720.
Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease.
2022
Le Guen Y, Belloy ME, Grenier-Boley B et al.
JAMA Neurol May 31, 2022. doi:10.1001/jamaneurol.2022.1166.
New insights into the genetic etiology of Alzheimer’s disease and related dementias.
2022
Bellenguez C, Küçükali F, Jansen IE, et al.
Nature Genetics 2022 Apr 4. doi: 10.1038/s41588-022-01024-z.
Benefits of Treatment with Ginkgo Biloba Extract EGb 761 Alone or Combined with Acetylcholinesterase Inhibitors in Vascular Dementia.
2022
García-Alberca JM, Mendoza S, Gris E.
Clinical Drug Investigation 2022, doi: 10.1007/s40261-022-01136-8.
Genomic Characterization of Host Factors Related to SARS-CoV-2 Infection in People with Dementia and Control Populations: The GR@ACE/DEGESCO Study.
2021
de Rojas I , Isabel Hernández I Laura Montreal L. Quintela I, Calero M et al.
Journal of Personalized Medicine 2021; 11: 1318. doi.org/10.3390/jpm11121318.
The Genetic Research in Alzheimer Disease (GERALD) Initiative Finds rs9320913 as a Neural eQTL of lincRNA AL589740.1.
2021
Lopez-Gutierrez L, García-Alberca J, Mendoza S et al.
International Journal of Alzheimer´s Disease 2021; doi.org/10.1155/2021/3064224.
Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores.
2021
de Rojas I, Moreno-Grau S, Tesi N et al.
Nature Communications 2021 Jun 7;12(1):3417. doi: 10.1038/s41467-021-22491-8.
A polygenic risk score for mosaic loss of chromosome Y susceptibility is associated with higher risk of MCI of AD conversión.
2021
García-González P, de Rojas I, Hernandez I et al.
Alzheimer´s Dementia 2021; DOI:10.1002/alz.053745.
Long runs of homozygosity are associated with Alzheimer’s disease.
2021
Moreno-Grau S, Maria Victoria Fernández MV, de Rojas I et al.
Translational Psychiatry 2021; Feb 24; 11(1):142. doi: 10.1038/s41398-020-01145-1
Large meta-analysis of genome-wide association studies expands knowledge of the genetic etiology of Alzheimer disease and highlights potential translational opportunities.
2020
Bellenguez C, Küçükali F, Jansen I, Andrade V, Moreno-Grau S et al.
medRxiv 2020; preprint doi: https://doi.org/10.1101/2020.10.01.20200659.
Factores de riesgo cardiovascular y deterioro cognitivo tras cirugía de revascularización coronaria sin circulación extracorpórea
2015
Pérez-Belmonte LM, San Román-Terán CM, Such M, Barbancho MA, Pérez-Díaz JM, Osuna-Sánchez J. García-Alberca JM, Lara JP
Cardiocore 2015 July DOI: 10.1016 / j.carcor.2015.06.005.
Autosomal Recessive Alzheimer’s disease (arAD): homozygosity mapping of genomic regions containing arAD loci.
2020
Moreno-Grau S, Fernández MV, de Rojas I, Hernández I, Farias F et al.
bioRxiv preprint 2020; doi: https://doi.org/10.1101/2020.02.10.941393.
White matter lesions and temporal atrophy are associated with cognitive and neuropsychiatric symptoms in patients with hypertension and Alzheimer´s disease.
2020
García‐Alberca JM, Mendoza S, Gris E, Royo JL, Cruz-Gamero JM, García-Casares N.
International Journal of Geriatric Psychiatry 2020; Doi.org/10.1002/gps.5366
Common variants in Alzheimer’s disease: Novel association of six genetic variants with AD and risk stratification by polygenic risk scores.
2019
de Rojas I, Moreno-Grau S, Tesi N, Grenier-Boley B et al.
medRxiv preprint 2019; doi: http://dx.doi.org/10.1101/19012021.
Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer’s disease and three causality networks: The GR@ACE project.
2019
Moreno-Grau S, de Rojas I, Hernández I, Quintela I, Montrreal L, Alegret M et al.
Alzheimer´s and Dementia 2019; 15: 1333-1347
Medial temporal lobe atrophy is independently associated with behavioural and psychological symptoms in Alzheimer’s disease.
2018
García-Alberca JM, Florido M, Cáceres M, Sánchez-Toro A, Lara JP, García-Casares N
Psychogeriatrics 2018;19:46-54.
Cognitive-behavioral treatment for depressed patients with Alzheimer´s disease. An open trial.
2017
García-Alberca JM
Archives of Gerontology and Geriatrics 2017; 71:1-8.
A Path Analysis of Dependence and Quality of Life in Alzheimer’s Disease.
2017
Garre-Olmo J, Vilalta-Franch J, Calvó-Perxas L, López-Pousa S; CoDep-AD Study Group
American Journal of Alzheimer´s Disease and Other Dementias 2017; 32(2):108-115.
Efectos psicológicos y conductuales del Alzheimer
2016
García-Alberca JM
Mente y Cerebro 2016; 79: 50-56.
Terapias no farmacológicas del Alzheimer
2016
García-Alberca JM
Mente y Cerebro 2016; 81: 80-87.
Cognitive intervention therapy as treatment for behaviour disorders in Alzheimer disease: Evidence on efficacy and neurobiological correlations
2015
García-AlbercaJM
Neurología 2015; 30: 8-15.
Bilateral brain reorganization with memantine and constraint-induced aphasia therapy in chronic post-stroke aphasia: An ERP study.
2015
Barbancho MA, Berthier ML, Navas-Sánchez P, Dávila G, Green-Heredia C, García-Alberca JM, Ruiz-Cruces R, López-González MV, Dawid-Milner MS, Pulvermüller F, Lara JP
Brain Lang. 2015; 145-146:1-10.
Dependence Scale for Alzheimer’s Disease: Relationship With Other Clinical Indicators and Psychometric Properties
2015
Garre-Olmo J, Vilalta-Franch J, Calvó-Perxas L, Monserrat-Vila S, López-Pousa S, theCoDep-ADStudyGroup
Journal of Geriatric Psychiatry and Neurology 2015; 28:117-125.
Assessment of Long-term Cognitive Impairment After Off-pump Coronary-Artery Bypass. Grafting and Related Risk Factors
2015
Pérez-Belmonte LM, San Román-Terán CM, Jiménez-Navarro M, Barbancho MA, García-AlbercaJM,LaraJP
Journal of the American Medical Directors Association 2015; 16: 263-269.
Neuropsychiatric Symptoms in Patients With Alzheimer’s Disease: The Role of Caregiver Burden and Coping Strategies.
2014
García-Alberca JM, Lara JP, Garrido V, Gris E, González-Herero V, Lara A.
American Journal of Alzheimer´s Disease and Other Dementias 2014; 29: 354-361.
Sleep disturbances in Alzheimer´s disease are associated with neuropsychiatric symptoms and antidementia treatment
2013
García-Alberca JM, Lara JP, Cruz B, Garrido V, Gris E, Barbancho MA
Journal of Nervous and Mental Disease 2013; 201: 251- 257.
The experience of caregiving: the influence of coping strategies on behavioral and psychological symptoms in patients with Alzheimer’s disease
2013
García-Alberca JM, Cruz B, Lara JP, Garrido V, Gris E, Lara A, González-Herero V
Aging and Mental Health 2013; 17: 615-622.
Deterioro cognitivo disejecutivo en pacientes con enfermedad coronaria: asociación con variables clínicas
2013
Lara Muñoz JP, Pérez-Belmonte E, Olalla Mercadé E, Gutiérrez de Loma J, Barbancho Fernández MA,García-Alberca JM, Laín JM, San Román CM
Neurología 2013; 28: 183.
Disengagement coping partially mediates the relationship between caregiver burden and anxiety and depression in caregivers of people with Alzheimer’s disease. Results from the MÁLAGA-AD study
2012
García-Alberca JM, Cruz B, Lara JP, Garrido V, Gris E, Lara A
Journal of Affective Disorders 2012: 136: 848-856.
Anxiety and depression are associated with coping strategies in caregivers of Alzheimer’s disease patients: results from the MÁLAGA-AD study
2012
García-Alberca JM, Cruz B, Lara JP, Garrido V, Lara V, Gris E
International Psychogeriatrics 2012; 24: 1325-1334.
Anxiety and depression in caregivers are associated with patient and caregiver characteristics in Alzheimer´s disease
2011
García-Alberca JM, Lara JP, Berthier M.
International Journal of Psychiatry in Medicine 2011; 41: 57-69.
Can impairment in memory, language and executive functions predict neuropsychiatric symptoms in Alzheimer’s disease (AD)? Findings from a cross-sectional study
2011
García-Alberca JM, Lara JP, Berthier ML, Cruz B, Barbancho MA, Green C, González-Barón S
Archives of Gerontology and Geriatrics 2011; 52: 264–269.
ERP evidence of therapy-related reorganization of language of patients with post stroke chronic aphasia
2011
Lara JP, Barbancho MA, Berthier ML, Green C, Navas P, David.Milner MS, García-Alberca JM, Ruiz-Cruces R, Pulvermüller F, Dávila G, González-Barón S
Clinical Neurophysiology 2011; 122 (Supp 1) S214-S215.
Perfil de síntomas psicológicos y conductuales en pacientes con enfermedad de Alzheimer y demencia vascular
2010
Lara Muñoz JP, García-Alberca JM, Berthier Torres ML
Alzheimer. Realidades e Investigación en Demencias 2010; 46:5-14.
Sintomatología neuropsiquiátrica y conductual en la enfermedad de Alzheimer. Revisión
2010
García-Alberca JM, Lara JP Muñoz, M Berthier Torres
Actas Españolas de Psiquiatría 2010; 38:212-222.
Caracterización de las alteraciones del sueño en pacientes con enfermedad de Alzheimer. Relación con tratamientos farmacológicos
2010
Lara JP, García-Alberca JM, Berthier M, Green C, Dawid-Milner MS, Dávila G, Pulvermüller F
Neurología 2010; 25: 10-11.
ERPs correlates of recovery from chronic post-stroke aphasia in patients treated with memantine and constraint-induced aphasia therapy
2009
Lara JP, Barbancho MA, Berthier M, Green C, Navas P, Dawid-Milner MS, Dávila G, García-Alberca JM, Pulvermüller F
European Journal of Neurology 2009; 16 (Suppl. 3): 335-624.
Normalización de potenciales relacionados con eventos tras el efecto beneficioso de la memantina en afásicos crónicos postictus
2009
Lara JP, Barbancho MA, Berthier ML, Green C, Navas P,Dawid-Milner MS, Dávila G, García-Alberca JM, Pulvermüller F, González-Baron S.
Revista de Neurología 200; 24: 621-621.
Prevalencia y comorbilidad de síntomas neuropsiquiátricos en la enfermedad de Alzheimery
2008
García-Alberca JM, Lara JP, González-Barón S, Barbancho MA, Porta D, Berthier M
Actas Españolas de Psiquiatría 2008; 36:265-270.
Perfil clínico de pacientes con enfermedad de Alzheimer atendidos en centros de día psicogeriátricos
2008
García-Alberca JM, Lara JP, González-Barón S, Barbancho MA, Porta D, Berthier M
Anales de Psiquiatría 2008; 24: 145-152.
Rivastigmina en la enfermedad de Alzheimer
2008
Berthier ML, Green C, García-Alberca JM, Lara JP
Medicina Clinica Monografías (Barc) 2008; 9:16-19.
Perfil de síntomas psicológicos y conductuales en pacientes con enfermedad de Alzheimer y demencia vascular
2008
Lara JP, García-Alberca JM, Berthier ML, Barbancho MA, González-Barón S
Neurología 2008; 23: 617-724
Evidencia neurofisiológica del efecto beneficioso de la memantina y terapia restringida del lenguaje en afásicos crónicos postictus; estudio doble ciego, aleatorizado y controlado con placebo
2008
Lara JP, Barbancho MA, Berthier M, Green C, Navas P, Dawid-Milner MS, Dávila G, García-Alberca JM, González-Barón S
Neurología 2008; 23: 617-724.
Mecanismos funcionales de desinhibición cognitiva en la enfermedad de alzheimer: estudio de caso-control con RMN 3T, PET y potenciales evocados cognitivos
2008
Berthier M, Green C, Boán J, Lara JP, Fernández L, Ruiz J A, Barbancho MA, Gómez J, Arbizu J, Dávila G, García-Alberca JM, Pulvermüller F
Neurología 2008; 23: 617-724.
Correlación entre el deterioro en memoria y funciones ejecutivas con los síntomas neuropsiquiátricos en pacientes con enfermedad de Alzheimer
2008
Lara JP, García-Alberca JM, González-Barón S, Berthier ML
Revista de Psiquiatría y Salud Mental 2008; 1: 93-93.
Demencia vascular: relación entre deterioro funcional y síntomas neuropsiquiátricos
2008
García-Alberca JM, Lara JP, Green C, González Barón S, Berthier M
Revista de Psiquiatría y Salud Mental 2008; 1: 93-94.
Relación entre la presencia de síntomas neuropsiquiátricos y la carga del cuidador en pacientes con enfermedad de Alzheimer
2008
García-Alberca JM, Lara JP, González Barón S, Berthier M
Revista de Psiquiatría y Salud Mental 2008; 1: 94-94.
Características sociodemográficas y clínicas de pacientes con enfermedad de Alzheimer y sus cuidadores principales
2008
García-Alberca JM, Lara P, González-Barón S, Berthier M
Málaga Científica 2008; 112: 32-37.
Influencia de los síntomas conductuales y psicológicos en la carga y sufrimiento del cuidador en un grupo de pacientes con enfermedad de Alzheimer
2007
García-Alberca JM, Lara JP, Porta D, González Barón S, Berthier M
Neurologia 2007, 22: 723-723.
Deterioro funcional y síntomas psicológicos y conductuales en un grupo de pacientes con demencia vascular
2007
García-Alberca JM, Lara JP, Green C, González Barón S, Berthier M
Neurología 2007, 22: 723-724.
Estudio en afásicos crónicos postictus del procesamiento del lenguaje mediante potenciales cognitivos relacionados con eventos
2007
Lara JP, Barbancho MA, Montes C, Berthier M, Green C, Dawid-Milner MS, García-Alberca JM, Pulvermüller F, González-Barón S
Neurología 2007, 22: 724-724.
Correlaciones entre funciones ejecutivas y de memoria y síntomas conductuales y psicológicos en un grupo de pacientes con enfermedad de Alzheimer
2007
Lara JP, García-Alberca JM, Barbancho MA, González-Barón S, Berthier M
Neurología 2007; 22: 804-804.
Trastornos neuropsiquiátricos y función cognitiva en la enfermedad de Alzheimer
2006
García-Alberca JM, González Barón S, Berthier M, Lara JP
Psiquiatría Biológica 2006; 13 (Supl. 3): 78-78.
Perfil cognitivo y síntomas conductuales y psicológicos en un grupo de pacientes con enfermedad de Alzheimer
2006
Lara JP, García-Alberca JM, González Barón S, Berthier M
Neurología 2006; 21: 677-678.
Frecuencia y gravedad de los síntomas conductuales y psicológicos en la enfermedad de Alzheimer
2005
García-Alberca JM, Berthier M, González Barón S, Lara JP
Revista de Neurología 2005; 41 (Supl 2): 55-95.
Prevalencia y evolución de los síntomas psicológicos y conductuales en la enfermedad de Alzheimer
2005
García-Alberca JM, González Barón S, Berthier M, Lara JP
Actas Españolas de Psiquiatría 2005, 33: 60-60.
Deterioro funcional y síntomas psicológicos y conductuales en un grupo de pacientes con enfermedad de Alzheimer
2005
Lara JP, García-Alberca JM, González Barón S, Berthier M
Neurología 2005; 20 (Supl 9): 513-514.
Cognitive–behavioural treatment for depression in Alzheimer’s disease patients: a case study
2016
García-Alberca JM
Psychogeriatrics 2017; 17:200-201.
(Click on the green buttons to navigate through the pages)